Cofactor Genomics
Cofactor closes the precision medicine gap with predictive diagnostics
Cofactor Genomics is active in the healthcare space based in St. Louis, MO, USA.
Profile
Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes.
Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data.
The team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM.
After a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US.
Current investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).
Cofactor Genomics is positioned in healthcare, a segment that rewards a clear, focused offering.
Its base of operations is St. Louis, MO, USA.
Directory data places it at the Summer 2015 stage.
Recorded headcount: 13 employees.
Directory analysis
Cofactor Genomics develops predictive diagnostics that leverage RNA data and predictive immune modeling to create biomarkers for improved patient outcomes. The company’s technology has been validated by CAP and AMP and published in the Journal of Molecular Diagnostics. A recent clinical study demonstrated its superiority in predicting immunotherapy responders.
Positioning: Cofactor Genomics positions itself as a niche player in precision medicine diagnostics, focusing on RNA-based biomarkers for immunotherapy response prediction. Its early validation and publication milestones suggest a solid scientific foundation, though market traction remains to be seen.
Note: Cofactor Genomics is a small, early-stage diagnostics startup based in St. Louis, MO.
Auto-generated directory analysis from public data · updated 6 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | St. Louis, MO, USA |
| Country | USA |
| Employees | 13 |
| Stage | Summer 2015 |
Website: cofactorgenomics.com
Browse related
Create a free account